Vaccibody – a novel generation of vaccinesVaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody is focusing on cancer vaccines and is partnering the technology within infection and veterinary use.
|
| Vaccibody in the press |
Aftenposten interviews Bjarne Bogen on the Vaccibody technology. Bogen, together with professor Inger Sandlie and Vaccibody CSO, Agnete Fredriksen are the three inventors of the Vaccibody technology. In Norwegian only. Read it here. |
| EU invests €30 million to boost vaccine research |
On 1 October 2011 the collaborative research programme – Advanced Immunization Technologies (ADITEC) - will start in order to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.ADITEC is co-funded with €30M by the European Commission to establish a robust platform for innovation in this key strategic area with a high socio-economic impact. Scientists from 42 research partners in 13 countries will collaborate in this new programme.
|
| Read more... |
